Your new post is loading...
The oncology landscape is evolving rapidly, driven by new science bringing treatment options for an expanded number of patients and redefining cancer as a large number of narrowly defined diseases. Most health systems are struggling to adapt and embrace this evolution, in particular the regulatory systems, diagnostic and treatment infrastructure, and financing mechanisms that are required to meet the needs of populations.
Over the past five years, 70 new oncology treatments have been launched and are being used to treat over 20 different tumor types. However, most of these drugs are not yet available in most countries, and even when they are registered, they may not be reimbursed.
The total cost of cancer therapeutics and medicines used in supportive care – measured at the ex-manufacturer price level before the application of rebates or other price concessions – reached $107 billion in 2015, representing an increase in constant dollars of 11.5% over the prior year. Not surprisingly, payers are seeking assurance of the value that result from their expenditure on these drugs and the associated services required for their appropriate use. This tension can be expected to be amplified over the next five years as a strong pipeline of clinically distinctive therapies reaches a growing number of patients around the world.
Over Twenty Tumor Types Are Being Treated With New Medicines That Have Been Launched in The Past Five Years
Over 586 molecules are in clinical development, up 63% over the past 10 years, with targeted agents making up 87% of the current pipeline.
A diverse set of over 500 companies are actively engaged in late phase oncology R&D, including most leading global companies and many newcomers.
Via Pharma Guy
You might also be interested in reading this article: "Obama’s Cancer ‘Moonshot’ vs the Catch-22 of Oncology"; http://sco.lt/6ixUsj
You might also be interested in reading this article: "Obama’s Cancer ‘Moonshot’ vs the Catch-22 of Oncology"; http://sco.lt/6ixUsj ;